mitoxantrone hydrochloride liposome + azacitidine + tislelizumab

This combination therapy consists of mitoxantrone hydrochloride liposome, azacitidine, and tislelizumab, and is primarily being investigated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Mitoxantrone hydrochloride liposome is a nanoparticle-encapsulated formulation of the anthracenedione antineoplastic agent mitoxantrone, which functions as a DNA intercalator and a topoisomerase II inhibitor, leading to double-strand DNA breaks and cell death. Azacitidine is a pyrimidine nucleoside analog that acts as a DNA methyltransferase inhibitor; it incorporates into DNA and RNA to induce epigenetic reprogramming through hypomethylation and exerts direct cytotoxic effects on abnormal hematopoietic cells. Tislelizumab is a humanized IgG4 monoclonal antibody designed to bind to the programmed cell death protein 1 (PD-1) receptor on T cells, preventing its interaction with PD-L1 and PD-L2 ligands and thereby restoring the immune system's ability to identify and destroy tumor cells. The triplet regimen aims to achieve synergistic anti-tumor activity by combining cytotoxic chemotherapy, epigenetic modulation, and immune checkpoint inhibition.

Brand names

Duoenda

Other names

mitoxantrone hydrochloride liposome + azacitidine + tislelizumab